ArticleCell metabolism2016
Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.
Article in Cell metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 73 citations in OpenAlex.
- Transcriptional Heterogeneity of Cardiac Remodeling Between Type 1 and Type 2 Diabetes.Biomedicines · 2026Article
- β-Cell Neogenesis From the Pancreatic Ductal Epithelium Revealed Dynamically by Long-term Intravital Imaging.Diabetes · 2025Article
- VDAC1 is a target for pharmacologically induced insulin hypersecretion in β cells.Cell reports · 2025Article
- A novel self-assembling peptide nanofiber hydrogel with glucagon-like peptide-1 functionality enhances islet survival to improve islet transplantation outcome in diabetes treatment.Journal of nanobiotechnology · 2024Article
- Spint1 disruption in mouse pancreas leads to glucose intolerance and impaired insulin production involving HEPSIN/MAFA.Nature communications · 2024Article
- Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.Acta pharmacologica Sinica · 2024Article
- The anterior chamber of the eye technology and its anatomical, optical, and immunological bases.Physiological reviews · 2024Review
- A human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes models.Nature communications · 2023Article
- Pancreatic islet protection at the expense of secretory function involves serine-linked mitochondrial one-carbon metabolism.Cell reports · 2023Article
- Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth.TouchREVIEWS in endocrinology · 2023Review
- Longitudinal monitoring of pancreatic islet damage in streptozotocin-treated mice with optical coherence microscopy.Biomedical optics express · 2023Article
- Nutrient Regulation of Pancreatic Islet β-Cell Secretory Capacity and Insulin Production.Biomolecules · 2022Review
- Inhibition of SGLT2 Preserves Function and Promotes Proliferation of Human Islets Cells In Vivo in Diabetic Mice.Biomedicines · 2022Article
- Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function.Handbook of experimental pharmacology · 2022Review
- Resetting the circadian clock of Alzheimer's miceFrontiers in physiology · 2022Article
- The Pancreatic ß-cell Response to Secretory Demands and Adaption to Stress.Endocrinology · 2021Review
- The Eye as a Transplantation Site to Monitor Pancreatic Islet Cell Plasticity.Frontiers in endocrinology · 2021Review
- Alpha cell regulation of beta cell function.Diabetologia · 2020Review
- Beta cell dysfunction in diabetes: the islet microenvironment as an unusual suspect.Diabetologia · 2020Review
- Current Progress and Perspective: Clinical Imaging of Islet Transplantation.Life (Basel, Switzerland) · 2020Review
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Incretin mimetics are frequently used in the treatment of type 2 diabetes because they potentiate β cell response to glucose. Clinical evidence showing short-term benefits of such therapeutics (e.g., liraglutide) is abundant; however, there have been several recent reports of unexpected complications in association with incretin mimetic therapy. Importantly, clinical evidence on the potential effects of such agents on the β cell and islet function during long-term, multiyear use remains lacking. We now show that prolonged daily liraglutide treatment of >200 days in humanized mice, transplanted with human pancreatic islets in the anterior chamber of the eye, is associated with compromised release of human insulin and deranged overall glucose homeostasis. These findings raise concern about the chronic potentiation of β cell function through incretin mimetic therapy in diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.